Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers

PURPOSE: Multiple cancers harbor genetic aberrations that impact AKT signaling. MK-2206 is a potent pan-AKT inhibitor with a maximum tolerated dose (MTD) previously established at 60mg on alternate days (QOD). Due to a long half-life (60-80h), a weekly (QW) MK-2206 schedule was pursued to compare in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Yap, Timothy A., Yan, Li, Patnaik, Amita, Tunariu, Nina, Biondo, Andrea, Fearen, Ivy, Papadopoulos, Kyriakos P., Olmos, David, Baird, Richard, Delgado, Liliana, Tetteh, Ernestina, Beckman, Robert A., Lupinacci, Lisa, Riisnaes, Ruth, Decordova, Shaun, Heaton, Simon P., Swales, Karen, deSouza, Nandita M, Leach, Martin O., Garrett, Michelle D., Sullivan, Daniel M., de Bono, Johann S., Tolcher, Anthony W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4233149/
https://ncbi.nlm.nih.gov/pubmed/25239610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0868
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados